Literature DB >> 7753054

International guide to drugs for Parkinson's disease.

W H Oertel1, R C Dodel.   

Abstract

Pharmacotherapy of Parkinson's disease (PD) has become so effective that patients with PD can enjoy a nearly normal life, including travel for several years. The degree of international travel of patients with PD and in particular the recent increased coordination between health systems in the European community call for a detailed information on the different antiparkinsonian drugs available worldwide. To provide an overview for physicians and patients on the diversity of preparations available in the different countries, we compiled the most commonly used substances along with their size of dosage and formula in an international guide to drugs for PD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7753054     DOI: 10.1002/mds.870100202

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  5 in total

Review 1.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

2.  The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors.

Authors:  Adrienne J Betz; Peter J McLaughlin; Melissa Burgos; Suzanne M Weber; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2007-06-27       Impact factor: 4.530

Review 3.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

4.  Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.

Authors:  A Machado; A J Herrera; J L Venero; M Santiago; R M de Pablos; R F Villarán; A M Espinosa-Oliva; S Argüelles; M Sarmiento; M J Delgado-Cortés; R Mauriño; J Cano
Journal:  ISRN Neurol       Date:  2011-04-17

5.  Multivariate genomic and transcriptomic determinants of imaging-derived personalized therapeutic needs in Parkinson's disease.

Authors:  Christophe Lenglos; Sue-Jin Lin; Yashar Zeighami; Tobias R Baumeister; Felix Carbonell; Yasser Iturria-Medina
Journal:  Sci Rep       Date:  2022-03-31       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.